Mizuho analyst Vamil Divan initiated coverage of Alkermes with a Neutral rating and $19 price target, saying he expects Vivitrol and Aristada to continue growing for the company, though he also does not expect significant upside above current estimates from either. Divan added that he also anticipates ALKS-3831 will be approved this year but, based on conversations with physicians and payer consultants, he thinks it will take time to commercialize effectively. The analyst also said that success with ALKS 4230 could transformer Alkermes, but the clinical data supporting it are "limited to date."